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Estimation of the glomerular filtration rate (GFR) by the MDRD (1) equation is now 
widely used in clinical practice. Guidelines (2) recommend that clinical laboratories 
compute and report estimated GFR by using such an estimating equation to facilitate 
detection of chronic kidney disease. However, several authors have shown that this 
formula should not be applied to patients with a normal renal function because it lacks 
accuracy and precision for GFRs over 60 ml/min/1.73 m² (3). All “normal” GFRs must 
be reported as “> 60 ml/min/1.73 m³” without any precision of the value (4). There are 
many explanations for this inaccuracy: the variation of the serum creatinine assay 
calibration (5), the fact that the patients enrolled in the MDRD study had a renal failure 
and that the relationship between creatinine and GFR are not the same in normal and 
renal failure populations (6) and finally the precision of the Jaffé methods (7). We have 
recently illustrated the impact of the critical difference concept for MDRD results with 
normal creatinine values (8). 
There is another consideration that, to our knowledge, has not been evaluated. 
Measurement uncertainty characterises the dispersion of the values that could 
reasonably be attributed to the measurand.  The evaluation of the measurement 
uncertainty is described in the ISO document Guide to the Expression of Uncertainty in 
Measurement (GUM). However, the application of this guide is, in practice, very 
difficult (9). There are two possible evaluations of the uncertainty: type A evaluation, 
that can be calculated by statistical means from repeated measurements and type B, 
which uses prior information like reported uncertainties of a reference material, 
calibration certificates, resolution, instability. 
In clinical biology, where we work with complex matrix like serum, we should combine 
both uncertainties to have a better estimation of the uncertainty with the formula u(G) = 












practice, we evaluate uA as the standard deviation of the quality controls realised on a 
long period of time, covering at least 3 reagent lots and all relevant instrument 
maintenance conditions, multiplied by a factor k (k=2 for a 95% confidence interval and 
k=3 for a 99% confidence interval). Type B uncertainty statement estimated and 
expressed according to GUM should be given by the manufacturer.  
We use the compensated kinetic Jaffé method for the creatinine measurement (Modular, 
Roche Diagnostics, Mannheim, Germany) in our laboratory. From November 2005 to 
July 2006, we have performed 1800 quality controls for the creatinine test, with a mean 
of 0.725  mg/dl and a standard deviation of 0.035 mg/dl. We can then evaluate u²A with 
a 95% confidence interval: (2 X 0.035)² = 0.0049 mg/dl.  
The uncertainty on the C.f.a.s calibrator at 4.39 mg/dl used to calibrate our creatinine 
kits is 0.0760 mg/dl (Roche Diagnostics Traceability and Uncertainty document for 
C.f.a.s Proteins, April 2006; reference method:GC-MS). We can then evaluate u²B at 
0.00578. 
The uncertainty of creatinine for our 0.725 mg/dl control is then = (0.0049 + 0.00578)1/2 
= 0.103 mg/dl. In other words, this means that the “true” value of our measurand is 
comprised between 0.622 and 0.828 mg/dl. As the relationship between GFR and 
creatinine is exponential, small variations of creatinine induce large variations in GFR. 
When the two latter values are introduced into the simplified MDRD formula for a 60 
years old man, the results are 140 and 101 ml/min/1.73 m², respectively. The absolute 
differences between these estimated GFRs and GFR estimated with 0.725 mg/dl which 
is 117 ml/min/1.73 m² are 23 and 17 ml/min/1.73m². 
Our approach is not free from criticism. In fact, a quality control is not a sample patient 
and our uncertainty is not the “true” uncertainty as determined by the GUM guidelines, 












We would have certainly observed a smaller uncertainty on the high level control. 
Indeed, the value of this control is closer than the value of the calibrator. Now, because 
of the exponential relation between GFR and creatinine, it is of importance that 
uncertainty in the low creatinine values is the smallest possible. We are then persuaded 
that creatinine reagents should be calibrated with at least three points, with one point 
near 1 mg/dl instead of the traditional two points calibration.  
Once again, our data show that one should be cautious when applying the MDRD 
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